Sequencing of Genes Involved in the Movement of Calcium across Human Skeletal Muscle Sarcoplasmic Reticulum: Continuing the Search for Genes Associated with Malignant Hyperthermia

The genetic basis of malignant hyperthermia (MH) is not fully characterised and likely involves more than just the currently classified mutations in the gene encoding the skeletal muscle ryanodine receptor (RYR1) and the gene encoding the α1 subunit of the dihydropyridine receptor (CACNA1S). In this paper we sequence other genes involved in calcium trafficking within skeletal muscle in patients with positive in vitro contracture tests, searching for alternative genes associated with MH. We identified four rare variants in four different genes (CACNB1, CASQ1, SERCA1 and CASQ2) encoding proteins involved in calcium handling in skeletal muscle in a cohort of 30 Australian MH susceptible probands in whom prior complete sequencing of RYR1 and CACNA1S had yielded no rare variants. These four variants have very low minor allele frequencies and while it is tempting to speculate that they have a role in MH, they remain at present variants of unknown significance. Nevertheless they provide the basis for a new set of functional studies, which may indeed identify novel players in MH.

[1]  K. Stowell,et al.  Comparison of pathogenicity prediction tools on missense variants in RYR1 and CACNA1S associated with malignant hyperthermia. , 2016, British journal of anaesthesia.

[2]  C. Müller,et al.  European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility. , 2015, British journal of anaesthesia.

[3]  P. Forget,et al.  The Changing Face of Malignant Hyperthermia: Less Fulminant, More Insidious , 2015, Anaesthesia and intensive care.

[4]  E. Ríos,et al.  The couplonopathies: A comparative approach to a class of diseases of skeletal and cardiac muscle , 2015, The Journal of general physiology.

[5]  Pawan Gupta,et al.  Next-generation Sequencing of RYR1 and CACNA1S in Malignant Hyperthermia and Exertional Heat Illness , 2015, Anesthesiology.

[6]  A. Bjorksten,et al.  Analysis of the Entire Ryanodine Receptor type 1 and Alpha 1 Subunit of the Dihydropyridine Receptor (CACNA1S) Coding Regions for Variants Associated with Malignant Hyperthermia in Australian Families , 2015, Anaesthesia and intensive care.

[7]  I. Carr,et al.  Advantage from massive parallel sequencing of RYR1 and CACNA1S in diagnostics of malignant hyperthermia susceptibility , 2014, BMC Anesthesiology.

[8]  G. Lamb,et al.  Sarcoplasmic reticulum Ca2+ uptake and leak properties, and SERCA isoform expression, in type I and type II fibres of human skeletal muscle , 2014, The Journal of physiology.

[9]  K. Stowell.  DNA Testing for Malignant Hyperthermia: The Reality and the Dream , 2014, Anesthesia and analgesia.

[10]  F. Lehmann-Horn,et al.  Functional and genetic characterization of clinical malignant hyperthermia crises: a multi-centre study , 2014, Orphanet Journal of Rare Diseases.

[11]  G. Lamb,et al.  Endogenous and maximal sarcoplasmic reticulum calcium content and calsequestrin expression in type I and type II human skeletal muscle fibres , 2013, The Journal of physiology.

[12]  S. Cannon,et al.  Skeletal muscle-specific T-tubule protein STAC3 mediates voltage-induced Ca2+ release and contractility , 2013, Proceedings of the National Academy of Sciences.

[13]  Jeremy W. Linsley,et al.  Stac3 is a component of the excitation-contraction coupling machinery and mutated in Native American myopathy , 2013, Nature Communications.

[14]  K. Beam,et al.  Impaired gating of an L-Type Ca(2+) channel carrying a mutation linked to malignant hyperthermia. , 2013, Biophysical journal.

[15]  B. Brandom,et al.  Ryanodine Receptor Type 1 Gene Variants in the Malignant Hyperthermia-Susceptible Population of the United States , 2013, Anesthesia and analgesia.

[16]  L. Weaver,et al.  An α‐helical C‐terminal tail segment of the skeletal L‐type Ca2+ channel β1a subunit activates ryanodine receptor type 1 via a hydrophobic surface , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  B. Engelen,et al.  Brody syndrome: A clinically heterogeneous entity distinct from Brody disease A review of literature and a cross-sectional clinical study in 17 patients , 2012, Neuromuscular Disorders.

[18]  B. Knollmann,et al.  Mechanism underlying catecholaminergic polymorphic ventricular tachycardia and approaches to therapy. , 2011, Journal of electrocardiology.

[19]  M. Casarotto,et al.  The ryanodine receptor: a pivotal Ca2+ regulatory protein and potential therapeutic drug target. , 2011, Current drug targets.

[20]  C. Antzelevitch,et al.  Identification of a novel loss-of-function calcium channel gene mutation in short QT syndrome (SQTS6). , 2011, European heart journal.

[21]  B. Flucher,et al.  Identification and functional characterization of malignant hyperthermia mutation T1354S in the outer pore of the Cavalpha1S-subunit. , 2010, American journal of physiology. Cell physiology.

[22]  Serafim Batzoglou,et al.  Identifying a High Fraction of the Human Genome to be under Selective Constraint Using GERP++ , 2010, PLoS Comput. Biol..

[23]  Martin Borggrefe,et al.  Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death. , 2010, Heart rhythm.

[24]  D. H. Kim,et al.  Increased store-operated Ca2+ entry in skeletal muscle with reduced calsequestrin-1 expression. , 2010, Biophysical journal.

[25]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[26]  R. Robinson,et al.  Genetic variation in RYR1 and malignant hyperthermia phenotypes. , 2009, British journal of anaesthesia.

[27]  D. Maclennan,et al.  Store overload‐induced Ca2+ release as a triggering mechanism for CPVT and MH episodes caused by mutations in RYR and CASQ genes , 2009, The Journal of physiology.

[28]  F. Protasi,et al.  Calsequestrin‐1: a new candidate gene for malignant hyperthermia and exertional/environmental heat stroke , 2009, The Journal of physiology.

[29]  C. Reggiani,et al.  Anesthetic‐and heat‐induced sudden death in calsequestrin‐1‐knockout mice , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  A. Dulhunty,et al.  Ca2+ signaling in striated muscle: the elusive roles of triadin, junctin, and calsequestrin , 2009, European Biophysics Journal.

[31]  A. Dulhunty,et al.  CONTROL OF MUSCLE RYANODINE RECEPTOR CALCIUM RELEASE CHANNELS BY PROTEINS IN THE SARCOPLASMIC RETICULUM LUMEN , 2009, Clinical and experimental pharmacology & physiology.

[32]  K. Beam,et al.  The Skeletal L-type Ca2+ Current Is a Major Contributor to Excitation-coupled Ca2+ entry , 2009, The Journal of general physiology.

[33]  G. Obermair,et al.  Auxiliary Ca(2+) channel subunits: lessons learned from muscle. , 2008, Current opinion in pharmacology.

[34]  E. Lehman,et al.  Cardiac Arrests and Deaths Associated with Malignant Hyperthermia in North America from 1987 to 2006: A Report from The North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States , 2008, Anesthesiology.

[35]  Anuradha Kalyanasundaram,et al.  SERCA pump isoforms: Their role in calcium transport and disease , 2007, Muscle & nerve.

[36]  B. Brandom.  Genetics of Malignant Hyperthermia , 2006, TheScientificWorldJournal.

[37]  M. Varsányi,et al.  The conformation of calsequestrin determines its ability to regulate skeletal ryanodine receptors. , 2006, Biophysical journal.

[38]  G. Obermair,et al.  The role of auxiliary dihydropyridine receptor subunits in muscle , 2005, Journal of Muscle Research & Cell Motility.

[39]  D. Haussler,et al.  Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. , 2005, Genome research.

[40]  A. Odermatt,et al.  Structure/Function Analysis of the Ca2+ Binding and Translocation Domain of SERCA1 and the Role in Brody Disease of the ATP2A1 Gene Encoding SERCA1 a , 1997, Annals of the New York Academy of Sciences.

[41]  F. Lehmann-Horn,et al.  In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: Results of testing patients surviving fulminant MH and unrelated low‐risk subjects , 1997, Acta anaesthesiologica Scandinavica.

[42]  C. van Broeckhoven,et al.  A genome wide search for susceptibility loci in three European malignant hyperthermia pedigrees. , 1997, Human molecular genetics.

[43]  A. George,et al.  Masseter Muscle Rigidity Associated with Glycine sup 1306 ‐to‐ Alanine Mutation in the Adult Muscle Sodium Channel alpha‐Subunit Gene , 1995, Anesthesiology.

[44]  A. George,et al.  Masseter Muscle Rigidity Associated with Glycine1306-to- Alanine Mutation in the Adult Muscle Sodium Channel α-Subunit Gene , 1995 .

[45]  C. van Broeckhoven,et al.  Mapping of a further malignant hyperthermia susceptibility locus to chromosome 3q13.1. , 1995, American journal of human genetics.

[46]  S. Scherer,et al.  Localization of the gene encoding the alpha 2/delta-subunits of the L-type voltage-dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families. , 1994, Human molecular genetics.

[47]  A. Localio,et al.  A Clinical Grading Scale to Predict Malignant Hyperthermia Susceptibility , 1994, Anesthesiology.

[48]  A. Olckers,et al.  Evidence for the localization of a malignant hyperthermia susceptibility locus (MHS2) to human chromosome 17q. , 1992, Genomics.

[49]  A. Olckers,et al.  Adult muscle sodium channel alpha-subunit is a gene candidate for malignant hyperthermia susceptibility. , 1992, Genomics.

[50]  M. Klein,et al.  Effects of caffeine on calcium release from the sarcoplasmic reticulum in frog skeletal muscle fibres. , 1990, The Journal of physiology.

[51]  M. Farrall,et al.  Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. , 1990, Nature.

[52]  M. Phillips,et al.  Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia , 1990, Nature.

[53]  M. Farrall,et al.  Localization of the malignant hyperthermia susceptibility locus to human chromosome 19ql2–13.2 , 1990, Nature.